GREAT POINT PARTNERS LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 130 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.

Quarter-by-quarter ownership
GREAT POINT PARTNERS LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$6,650,621
+1.7%
601,322
+13.7%
1.30%
+1.6%
Q4 2022$6,541,875
+346.5%
528,850
+403.7%
1.28%
+263.2%
Q3 2022$1,465,000
-96.7%
105,000
-73.8%
0.35%
-92.0%
Q1 2019$44,744,000
+122.0%
400,000
+100.0%
4.43%
+73.8%
Q4 2018$20,158,000
+56.9%
200,000
+100.0%
2.55%
-44.7%
Q1 2016$12,847,000100,0004.61%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2023
NameSharesValueWeighting ↓
WHITE SQUARE CAPITAL LLP 65,500$7,117,00011.05%
Ghost Tree Capital, LLC 70,000$7,606,0001.83%
Carmignac Gestion 2,022,792$219,776,0001.71%
Orbimed Advisors 1,120,000$121,688,0001.55%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 29,555$3,211,0001.45%
Parametrica Management Ltd 10,814$1,175,0001.16%
BB BIOTECH AG 255,719$27,784,0001.03%
SECTORAL ASSET MANAGEMENT INC 74,150$8,056,0000.89%
ALTRINSIC GLOBAL ADVISORS LLC 188,904$20,524,0000.76%
FALCON POINT CAPITAL, LLC 45,005$4,890,0000.66%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders